Bacteraemia due to extended-spectrum β-lactamase-producing Escherichia coli (ESBL-EC) in cancer patients: Clinical features, risk factors, molecular epidemiology and outcome

Journal of Antimicrobial Chemotherapy

Volumn 65, Issue 2, 2009, Pages 333-341

  Gudiol, Carlota ^a,b   Calatayud, Laura ^a   Garcia Vidal, Carolina ^a,b   Lora Tamayo, Jaime ^a,b   Cisnal, María ^a   Duarte, Rafael ^c   Arnan, Montserrat ^c   Marin, Mar ^c   Carratalá, Jordi ^a,b   Gudio, Francesc ^a,b  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Bloodstream infection; Multidrug resistant; Neutropenia

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; BETA LACTAM; BETA LACTAMASE INHIBITOR; CARBAPENEM DERIVATIVE; EXTENDED SPECTRUM BETA LACTAMASE; POLYPEPTIDE ANTIBIOTIC AGENT; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; CANCER PATIENT; CAUSAL ATTRIBUTION; CLINICAL FEATURE; CONTROLLED STUDY; CORTICOSTEROID THERAPY; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTION; FEMALE; GRAM NEGATIVE SEPSIS; HIGH RISK PATIENT; HUMAN; HUMAN CELL; INFECTION SENSITIVITY; INTENSIVE CARE; MAJOR CLINICAL STUDY; MALE; MOLECULAR EPIDEMIOLOGY; MORTALITY; NEUTROPENIA; NONHUMAN; OUTCOME ASSESSMENT; PROGNOSIS; RISK FACTOR; SEX DIFFERENCE; SOLID TUMOR;

EID: 77950261972     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkp411     Document Type: Article

References (31)

1. Calatayud L, Arnan M, Liñares J et al. Prospective study of fecal colonization by extended-spectrum b-lactamase-producing Escherichia coli in neutropenic patients with cancer. Antimicrob Agents Chemother 2008; 52: 4187-90.
2. Valverde A, Coque TM, Sánchez-Moreno MP et al. Dramatic increase in prevalence of fecal carriage of extended-spectrum b-lactamaseproducing Enterobacteriaceae during nonoutbreak situations in Spain. J Clin Microbiol 2004; 42: 4769-75.
3. Rodríguez-Baño J, López-Cerero L, Navarro MD et al. Faecal carriage of extended-spectrum b-lactamase-producing Escherichia coli: prevalence, risk factors and molecular epidemiology. J Antimicrob Chemother 2008; 62: 1142-49.
4. Paterson DL, Bonomo RA. Extended-spectrum b-lactamases: a clinical update. Clin Microbiol Rev 2005; 18: 657-86.
5. Munford RS. Severe sepsis and septic shock. In: Kasper DL, Braunwald E, Hanser SL et al., eds. Harrison's Principles of Internal Medicine. 16th edn. New York: McGraw-Hill, 2005; 1607-12.
6. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: Sixteenth Informational Supplement M100-S16. CLSI, Wayne, PA, USA, 2006.
7. Tenover FC, Arbeit RD, Goering RV et al. Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. J Clin Microbiol 1995; 33: 2233-9.
8. Fang H, Ataker F, Hedin G et al. Molecular epidemiology of extended-spectrum b-lactamases among Escherichia coli isolates collected in a Swedish hospital and its associated health care facilities from 2001 to 2006. J Clin Microbiol 2008; 46: 707-12.
9. Matthew M, Harris AM, Marshall MJ et al. The use of analytical isoelectric focusing for detection and identification of β-lactamases. J Gen Microbiol 1975; 88: 169-78.
10. Hosmer DW, Lemeshow S. Logistic regression: variable selection. In: Hosmer DW, Lemeshow S, eds. Applied Logistic Regression. 2nd edn. New York: John Wiley & Sons, 2000; 92-115.
11. Rodríguez-Baño J, Navarro MD, Romero L et al. Bacteremia due to extended-spectrum b-lactamase-producing Escherichia coli in the CTX-M era: a new clinical challenge. Clin Infect Dis 2006; 43: 1407-14.
12. Ho PL, Chan WM, Tsang KWT et al. Bacteremia caused by Escherichia coli producing extended-spectrum β-lactamase: a case-control study of risk factors and outcomes. Scand J Infect Dis 2002; 34: 567-73.
13. Kang CI, Kim SH, Park WB et al. Bloodstream infections due to extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumonia: risk factors for mortality and treatment outcome, with special emphasis on antimicrobial therapy. Antimicrob Agent Chemother 2004; 48: 4574-81.
14. Peña C, Gudiol C, Tubau F et al. Risk-factors for acquisition of extended-spectrum β-lactamase producing Escherichia coli among hospitalised patients. Clin Microbiol Infect 2006; 12: 279-84.
15. Ortega M, Marco F, Soriano A et al. Analysis of 4758 Escherichia coli bacteremia episodes: predictive factors for isolation of an antibiotic-resistant strain and the impact on outcome. J Antimicrob Chemother 2009; 63: 568-74.
16. Pitout JD, Laupland KB. Extended-spectrum β-lactamaseproducing Enterobacteriaceae: an emerging public-health concern. Lancet Infect Dis 2008; 8: 159-66.
17. Trecarichi EM, Tumbarello M, Spanu T et al. Incidence and clinical impact of extended-spectrum-β-lactamase (ESBL) production and fluoroquinolones resistance in bloodstream infections caused by Escherichia coli in patients with hematological malignancies. J Infect 2009; 58: 299-307.
18. Siu LK, Lu PL, Hsueh PR et al. Bacteremia due to extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a pediatric oncology ward: clinical features and identification of different plasmids carrying both SHV-5 and TEM-1 genes. J Clin Microbiol 1999; 37: 4020-27.
19. Kim YK, Pai H, Lee HJ et al. Bloodstream infections by extended-spectrum b-lactamase-producing Escherichia coli and Klebsiella pneumoniae in children: epidemiology and clinical outcome. Antimicrob Agent Chemother 2002; 46: 1481-91.
20. Rodríguez-Baño J, Alcalá JC, Cisneros JM et al. Community infections caused by extended-spectrum β-lactamase-producing Escherichia coli. Arch Intern Med 2008; 168: 1897-902.
21. Ariffin H, Navaratnam P, Mohamed M et al. Ceftazidimeresistant Klebsiella pneumoniae bloodstream infection in children with febrile neutropenia. Int J Infect Dis 1999; 4: 21-5.
22. Rodríguez-Baño J, Navarro MD, Romero L et al. Risk-factors for emerging bloodstream infections caused by extended-spectrum β-lactamase-producing Escherichia coli. Clin Microbiol Infect 2008; 14: 180-3.
23. Paterson DL, Ko WC, Von Gottberg A et al. Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum β-lactamases: implications for the clinical microbiology laboratory. J Clin Microbiol 2001; 39: 2206-12.
24. Peña C, Gudiol C, Calatayud L et al. Infections due to Escherichia coli producing extended-spectrum β-lactamase among hospitalised patients: factors influencing mortality. J Hosp Infect 2008; 68: 116-22.
25. Schiappa DA, Hayden MG, Matushek G et al. Ceftazidime-resistant Klebsiella pneumoniae and Escherichia coli bloodstream infection: a case-control and molecular epidemiologic investigation. J Infect Dis 1996; 174: 529-36.
26. Hyle EP, Lipworth AD,Zaoutis TE et al. Impact of inadequate initial antimicrobial therapy on mortality in infections due to extendedspectrum β-lactamase-producing enterobacteriaceae: variability by site of infection. Arch Intern Med 2005; 165: 1375-80.
27. Paterson DL. Recommendations for treatment of severe infections caused by Enterobacteriaceae producing extended-spectrum β-lactamases (ESBLs). Clin Microbiol Infect 2000; 6: 460-3.
28. Hughes WT, Armstrong D, Bodey GP et al. 2002 Guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002; 34: 730-51.
29. Jeon MH, Choi SH, Kwak YG et al. Risk factors for the acquisition of carbapenem-resistant Escherichia coli among hospitalized patients. Diagn Microbiol Infect Dis 2008; 62: 402-6.
30. Falagas ME, Rafailidilis PI, Kofteridis D et al. Risc factors of carbapenem-resistant Klebsiella pneumoniae infections: a matched-control study. J Antimicrob Chemother 2007; 60: 1124-30.
31. Troillet N, Samore MH, Carmeli Y. Imipenem-resistant Pseudomonas aeruginosa: risk factors and antibiotic susceptibility patterns. Clin Infect Dis 1997; 25: 1094-8.